News Sentiment

CMMB sentiment intelligence

Chemomab Therapeutics Ltd DRC news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 60 Balanced news tone 45 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 1.56 Week of 17 Jul 2026
Weighted tone 60/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Earnings

74/100 classification confidence.

Company focus 36

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend active

-10.3% over one week, +2.6% over four weeks, trend active, and below fair value.

Latest direct headline Positive

Chemomab Therapeutics (CMMB) Q3 2025 earnings summary

Market Reaction

Price moving ahead of tone

68/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Earnings 74/100 classification
One-week reaction -10.3% Price reacting lower
Trend fit Trend active 2.6% over four weeks
Fair value -59.3% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 19
Neutral 25
Negative 1

Relevance

Why the article matched

Direct first
Direct company coverage 36
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Quartr 6
Market source 6
Finviz 5
TradingView 4
Stock Titan 3
Moomoo 3
GlobeNewswire 3
dars.gov.et 2

Event Lens

What the news is about

Classified themes
Earnings 20
Deals and strategy 10
Market update 10
Analyst action 4
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-45 of 45
Benzinga Direct company coverage

11 Health Care Stocks Moving In Thursday's Intraday Session

This article lists several healthcare stocks that experienced significant price movements during Thursday's intraday trading session. It highlights both gainers, such as Chemomab Therapeutics and Liminatus Pharma, and decliners, including Elicio Therapeutics and Profusa, detailin

Tone
Positive 70/100
Event
Market update
Published
02 Jul 2026 17:09
Source
Benzinga
TradingView Direct company coverage

CMMB Forecast — Price Target — Prediction for 2027

This article provides the forecast and price target for Chemomab Therapeutics Ltd. (CMMB) on the Nasdaq Stock Market. One analyst currently offers a 1-year price forecast, with a price target of 5.00, although maximum and minimum estimates are not provided. The article also touch

Tone
Neutral 50/100
Event
Analyst action
Published
29 Jun 2026 02:39
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of Chemomab Therapeutics Ltd. – NASDAQ:CMMB

The article provides the "Enterprise value to revenue forward" for Chemomab Therapeutics Ltd. (NASDAQ: CMMB). It is presented on the TradingView platform, which offers financial data, charting tools, and community features for various markets including stocks, ETFs, and cryptocur

Tone
Neutral 50/100
Event
Earnings
Published
28 Jun 2026 08:10
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Chemomab Therapeutics Ltd. Sponsored ADR – MUN:2QV

This article provides financial information for Chemomab Therapeutics Ltd. Sponsored ADR (MUN:2QV), specifically focusing on its forward price-to-earnings ratio. It indicates that the current market for this stock is closed and no trades have occurred. The data is sourced from IC

Tone
Neutral 50/100
Event
Earnings
Published
28 Jun 2026 00:10
Source
TradingView